This database contains 60 studies, archived under the term: "France"
Click here to filter this large number of results.
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Background: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without […]
Sharing meals with institutionalized people with dementia: A natural experiment
Nutritional deficiency can have dramatic effects on the physical and psychological status of older adults. Although food supplements can enhance nutritional status, several authors suggest that more ecological means could also have beneficial impacts. Therefore, a natural experiment was conducted to study the impact of changed mealtime experiences for people with Alzheimer-type dementia. Two special […]
Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer’s disease
Dubois, Bruno,
Zaim, Mohammed,
Touchon, Jacques,
Vellas, Bruno,
Robert, Philippe,
Murphy, Michael F.,
Pujadas-Navinés, Francesc,
Rainer, Michael,
Soininen, Hilkka,
Riordan, Henry J.,
Kanony-Truc, Claire
New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]
Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study
Beauchet, Olivier,
Launay, Cyrille P.,
Allali, Gazan,
Watfa, Gilles,
Gallouj, Karim,
Herrmann, François R.,
Annweiler, Cedric
Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]
Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study
Dubois, Bruno,
Tolosa, Eduardo,
Katzenschlager, Regina,
Emre, Murat,
Lees, Andrew J.,
Schumann, Günther,
Pourcher, Emmanuelle,
Gray, Julian,
Thomas, Gail,
Swartz, Jina,
Hsu, Timothy,
Moline, Margaret L.
Parkinson’s disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and […]
Healing gardens and cognitive behavioral units in the management of Alzheimer’s disease patients: the Nancy experience
Rivasseau Jonveaux, T.,
Batt, M.,
Fescharek, R.,
Benetos, A.,
Trognon, A.,
Bah Chuzeville, S.,
Pop, A.,
Jacob, C.,
Yzoard, M.,
Demarche, L.,
Soulon, L.,
Malerba, G.,
Bouvel, B.
The French Alzheimer Plan 2008-2012 anticipates the implementation of new Units specialized in cognitive rehabilitation and psycho-behavioral therapy of Alzheimer’s disease (AD) patients. Conceived for AD and other dementia patients of all ages, their objectives are to propose a cognitive rehabilitation program, to prevent or treat psycho-behavioral crises, and to provide support and educational therapy […]
Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease
Fehlbaum-Beurdeley, Pascale,
Sol, Olivier,
Désiré, Laurent,
Touchon, Jacques,
Dantoine, Thierry,
Vercelletto, Martine,
Gabelle, Audrey,
Jarrige, Anne-Charlotte,
Haddad, Raphaël,
Lemarié, Jean Christophe,
Zhou, Weiyin,
Hampel, Harald,
Einstein, Richard,
Vellas, Bruno
Biomarkers have gained an increased importance in the past years in helping physicians to diagnose Alzheimer’s disease (AD). This study was designed to identify a blood-based, transcriptomic signature that can differentiate AD patients from control subjects. The performance of the signature was then evaluated for robustness in an independent blinded sample population. RNA was extracted […]
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease
Gillette-Guyonnet, Sophie,
Andrieu, Sandrine,
Dantoine, Thierry,
Dartigues, Jean-François,
Touchon, Jacques,
Vellas, B.
Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]